Evaluation of bronchial mucosa involvement in sarcoidosis patients using 18F-FDG PET-CT
Abstract：Objective To explore the value of 18F-FDG PET-CT in evaluating bronchial mucosa involvement in patients with saroidosis. Methods A retrospective analysis was conducted among 6 sarcoidosis patients with and 14 patients without bronchial mucosa involvement to collect the data including the standard uptake value (SUVMax/Mean) of 18F-FDG, serum angiotensin converting enzyme (sACE), and proportion of lymphocytes and CD4+/CD8 +T lymphocyte ratio in bronchoalveolar lavage fluid (BALF). Results The lung focal SUV (Max/Mean) was higher in patients with bronchial mucosa involvement than those without (7.04 ± 5.83/5.00 ± 4.69 vs 5.68 ± 3.66/3.82 ± 2.39), but such differences were not statistically significant (P=0.565/0.495). The SUV(Max/Mean) of the hilum of the lung and the mediastina lymph nodes were significantly higher in patients with bronchial mucosa involvement (13.28±5.57/10.48±4.43 vs 6.20±1.77/4.52±1.43, P=0.0003/0.0002;13.84±4.35/9.69±2.74 vs 7.16±2.52/5.28±1.77, P=0.0004/0.0004). The level of sACE and CD4+/CD8 + T lymphocyte ratio in BALF were also significantly higher in patients with bronchial mucosa involvement (60.58 ± 16.3 vs 49.16 ± 13.3 IU/L, P=0.045;7.30 ± 5.0 vs 2.90 ± 3.1, P=0.026). The proportion of lymphocytes in BALF was comparable between the patients with and without bronchial mucosa involvement (44.10±10.3%vs 35.30 ± 12.5%, P=0.148). Conclusions For patients with saroidosis, 18F-FDG PET-CT is useful in evaluating bronchial mucosa involvement, which is one of the key features of active sarcoidosis.
Keywords：bronchial mucosasaroidosis18F-FDGPET
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1650-1653,1667 )